On May 2, 2018 Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, reported that Edward Wirth III, M.D., Ph.D., Asterias’ Chief Medical Officer, will present previously announced 12-month safety and efficacy results for Cohort 2 (subjects with AIS-A grade cervical spinal cord injury and dosed with 10 million AST-OPC1 cells) from the company’s ongoing SCiStar Phase 1/2a study of AST-OPC1 in complete cervical spinal cord injury at the American Spinal Injury Association (ASIA) 2018 Annual Meeting, which is being held during May 2-4, 2018 in Rochester, Minnesota.
(Press release, Asterias Biotherapeutics, MAY 2, 2018, View Source;date=May+02%2C+2018&title=Asterias+Biotherapeutics+to+Present+Safety+and+Efficacy+Data+from+AST-OPC1+SCiStar+Study+at+the+American+Spinal+Injury+Association+%28ASIA%29+2018+Annual+Meeting+ [SID1234525939])
The details of the presentation are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: 12-Month Safety and Efficacy Results from the SCiStar Study – A Phase 1/2a Trial of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells (AST-OPC1) in Patients with Subacute Cervical Spinal Cord Injury
Date: Thursday, May 3, 2018
Time: 8:00 am – 9:30 am CDT